生物活性 | |||
---|---|---|---|
描述 | Vancomycin is one of only a few antibiotics available to treat patients infected with methicillin-resistant Staphylococcus aureus and methicillin-resistant, coagulase-negative Staphylococcus species[3]. Vancomycin inhibits the second stage of cell wall synthesis of susceptible bacteria, alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis. Enhancement of antimicrobial activity has been demonstrated with the combination of vancomycin and an aminoglycoside against Staph. aureus, Str. bovis, enterococci and viridans streptococci. The combination of vancomycin and rifampicin are antagonistic to most strains of Staph. aureus, though indifference and occasionally synergism have been shown, but is synergistic against strains of Staph. epidermidis. It shows indifference against enterococci. Vancomycin and fusidic acid are indifferent against Staph. Aureus[4]. Vancomycin improved clinical scores and histopathology acutely but was associated with poor outcome posttreatment in C. difficile-infected mice. Decreasing vancomycin exposure may decrease relapse and improve survival in CDI (Clostridium difficile infection)[5]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00437580 | Vancomycin Resistant Enterococ... 展开 >>cus Intestinal Carriage 收起 << | Phase 4 | Unknown | August 2009 | France ... 展开 >> Service des Maladies infectieuses et tropicales Recruiting Hôpital Gabriel Montpied, Clermont-Ferrand, France, 63003 收起 << |
NCT00295178 | Cellulitis | Phase 4 | Completed | - | United States, Georgia ... 展开 >> Joseph Still Research Foundation Augusta, Georgia, United States, 30909 收起 << |
NCT01661361 | - | Unknown | December 2012 | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
0.69mL 0.14mL 0.07mL |
3.45mL 0.69mL 0.35mL |
6.90mL 1.38mL 0.69mL |
参考文献 |
---|